Virility Medical Ltd.

Virility Medical Ltd. is a healthcare company focused on enhancing sexual health through innovative technology. Their premier product, the in2 device, is designed to improve sexual wellbeing by addressing issues such as premature ejaculation. Established in 2016 in Israel, Virility Medical Ltd.

specializes in developing solutions for sexual health. The company has engaged in three funding rounds, with the latest being a Series C round in July 2022, where they raised USD 10. 00 mn from Migdal Insurance Company and Arkin Holdings. The firm has not undergone significant pivots in its business strategy, and it operates independently without known subsidiaries.

Virility Medical specializes in sexual health, offering the in2 device, a clinically proven and FDA-cleared wearable that enhances sexual wellbeing by utilizing muscle stimulation technology to help delay ejaculation. This device allows users to effectively contract their pelvic-floor muscles, providing a drug-free solution for premature ejaculation. The in2 device is marketed and sold directly to consumers in the United States and Israel. Virility Medical employs a direct-to-consumer sales model, making the in2 device available for purchase through their online store in the United States and Israel.

Revenue is primarily generated from sales of this clinically proven wearable, with straightforward transactions that allow consumers to buy directly from the company, ensuring transparency in pricing and access. Following the recent Series C funding of USD 10. 00 mn in July 2022, Virility Medical plans to utilize these funds to further enhance their product offerings and increase market reach. The company is focused on designing new products to expand its portfolio in sexual health.

Additionally, they aim to enter new geographic regions beyond the United States and Israel, although specific markets and timelines have not been detailed.